Literature DB >> 21320757

Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?

Laura Kuyper1, M-J Milloy, Brandon D L Marshall, Ruth Zhang, Thomas Kerr, Julio S G Montaner, Evan Wood.   

Abstract

The delivery of antiretroviral therapy (ART) to injection drug users (IDU) may be influenced by provider concerns regarding the potential for increased HIV-related risk behavior following the initiation of HIV treatment. We evaluated whether ART initiation was associated with changes in syringe lending patterns among a long-term prospective cohort of HIV-positive IDU in Vancouver, Canada. Among 380 ART-naïve individuals eligible for this analysis, the median age was 34.2 (interquartile range [IQR] 27.7-40.8), 171 (45.0%) were female, and the median follow-up duration was 60 months (IQR=18-113). Between May 1996 and April 2008, 260 (68.4%) participants initiated ART. In a generalized linear mixed-effects model which compared each individual's likelihood of sharing syringes prior to and following the initiation of ART, syringe lending was not significantly associated with ART initiation in unadjusted (odds ratio=0.72, 95% CI: 0.38-1.36) or adjusted (odds ratio=0.78, 95% CI: 0.42-1.45) analyses. Concerns regarding increased injection risk behaviors following the initiation of ART were not observed in this setting.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320757      PMCID: PMC3053580          DOI: 10.1016/j.addbeh.2011.01.022

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  25 in total

Review 1.  Antiretroviral therapy for drug users.

Authors:  S M Clarke; F M Mulcahy
Journal:  Int J STD AIDS       Date:  2000-10       Impact factor: 1.359

2.  Staging for antiretroviral therapy among HIV-infected drug users.

Authors:  Evan Wood; Robert S Hogg; Simon Bonner; Thomas Kerr; Kathy Li; Anita Palepu; Silvia Guillemi; Martin T Schechter; Julio S G Montaner
Journal:  JAMA       Date:  2004-09-08       Impact factor: 56.272

3.  Sexual behavior changes and protease inhibitor therapy. SEROCO Study Group.

Authors:  M Miller; L Meyer; F Boufassa; A Persoz; A Sarr; M Robain; A Spira
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

4.  Protease inhibitor combination therapy and decreased condom use among gay men.

Authors:  Ralph J DiClemente; Ellen Funkhouser; Gina Wingood; Hala Fawal; Scott D Holmberg; Sten H Vermund
Journal:  South Med J       Date:  2002-04       Impact factor: 0.954

5.  Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users.

Authors:  A-D Bouhnik; J P Moatti; D Vlahov; H Gallais; P Dellamonica; Y Obadia
Journal:  J Epidemiol Community Health       Date:  2002-05       Impact factor: 3.710

6.  Impact of HIV infection on mortality in a cohort of injection drug users.

Authors:  M W Tyndall; K J Craib; S Currie; K Li; M V O'Shaughnessy; M T Schechter
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-01       Impact factor: 3.731

7.  Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review.

Authors:  Nicole Crepaz; Trevor A Hart; Gary Marks
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

8.  Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users.

Authors:  A Loughlin; L Metsch; L Gardner; P Anderson-Mahoney; M Barrigan; S Strathdee
Journal:  AIDS Care       Date:  2004-05

9.  Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.

Authors:  Waimar Tun; Stephen J Gange; David Vlahov; Steffanie A Strathdee; David D Celentano
Journal:  Clin Infect Dis       Date:  2004-04-05       Impact factor: 9.079

10.  Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Authors:  Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  9 in total

1.  Longitudinal Factors Associated with Used Syringe Lending Among HIV-Positive Antiretroviral Therapy-Naïve People Who Inject Drugs in a Canadian Setting.

Authors:  Ezequiel Blumenkrans; M Eugenia Socías; Lindsey Richardson; Thomas Kerr; Jean Shoveller; Julio Montaner; M-J Milloy
Journal:  AIDS Behav       Date:  2020-07

2.  Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review.

Authors:  Katrina Bouzanis; Siddharth Joshi; Cynthia Lokker; Sureka Pavalagantharajah; Yun Qiu; Hargun Sidhu; Lawrence Mbuagbaw; Majdi Qutob; Alia Henedi; Mitchell A H Levine; Robin Lennox; Jean-Eric Tarride; Dale Kalina; Elizabeth Alvarez
Journal:  BMJ Open       Date:  2021-09-23       Impact factor: 3.006

3.  Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.

Authors:  Tsung-chieh Fu; Ryan P Westergaard; Bryan Lau; David D Celentano; David Vlahov; Shruti H Mehta; Gregory D Kirk
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

4.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Authors:  Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

5.  The unrealized potential of addiction science in curbing the HIV epidemic.

Authors:  Nora D Volkow; Ruben D Baler; Jacques L Normand
Journal:  Curr HIV Res       Date:  2011-09       Impact factor: 1.581

Review 6.  Responding to global stimulant use: challenges and opportunities.

Authors:  Michael Farrell; Natasha K Martin; Emily Stockings; Annick Bórquez; Javier A Cepeda; Louisa Degenhardt; Robert Ali; Lucy Thi Tran; Jürgen Rehm; Marta Torrens; Steve Shoptaw; Rebecca McKetin
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

7.  Gay and bisexual men's awareness and knowledge of treatment as prevention: findings from the Momentum Health Study in Vancouver, Canada.

Authors:  Allison Carter; Nathan Lachowsky; Ashleigh Rich; Jamie I Forrest; Paul Sereda; Zishan Cui; Eric Roth; Angela Kaida; David Moore; Julio Sg Montaner; Robert S Hogg
Journal:  J Int AIDS Soc       Date:  2015-08-11       Impact factor: 5.396

8.  Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis.

Authors:  M-J Milloy; Thomas Kerr; Kate Salters; Hasina Samji; Silvia Guillemi; Julio Montaner; Evan Wood
Journal:  BMC Infect Dis       Date:  2013-12-01       Impact factor: 3.090

9.  Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis.

Authors:  Kathryn E Lancaster; Irving F Hoffman; Brett Hanscom; Tran Viet Ha; Kostyantyn Dumchev; Hepa Susami; Scott Rose; Vivian F Go; Sarah A Reifeis; Katie R Mollan; Michael G Hudgens; Estelle M Piwowar-Manning; Paul Richardson; Sergii Dvoriak; Zubairi Djoerban; Tetiana Kiriazova; Oleksandr Zeziulin; Samsuridjal Djauzi; Chu Viet Ahn; Carl Latkin; David Metzger; David N Burns; Jeremy Sugarman; Steffanie A Strathdee; Susan H Eshleman; William Clarke; Deborah Donnell; Lynda Emel; Lisa E Sunner; Laura McKinstry; Nirupama Sista; Erica L Hamilton; Jonathan P Lucas; Bui D Duong; Nguyen Van Vuong; Riza Sarasvita; William C Miller
Journal:  J Int AIDS Soc       Date:  2018-10       Impact factor: 5.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.